EP1098653A2 - Subcutaneous medroxyprogesterone acetate for contraception - Google Patents

Subcutaneous medroxyprogesterone acetate for contraception

Info

Publication number
EP1098653A2
EP1098653A2 EP99933540A EP99933540A EP1098653A2 EP 1098653 A2 EP1098653 A2 EP 1098653A2 EP 99933540 A EP99933540 A EP 99933540A EP 99933540 A EP99933540 A EP 99933540A EP 1098653 A2 EP1098653 A2 EP 1098653A2
Authority
EP
European Patent Office
Prior art keywords
female
medroxyprogesterone acetate
progestogen
effective amount
contraceptively effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99933540A
Other languages
German (de)
French (fr)
Inventor
Hendrik J. De Koning Gans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of EP1098653A2 publication Critical patent/EP1098653A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Definitions

  • the present invention is a subcutaneous method for adrninistering medroxyprogesterone acetate for female contraceptive use.
  • Contraception, 56, 353-359 also discloses a clinical study of medroxyprogesterone acetate (25 mg) and estradiol cypionate (5 mg) by monthly IM injection for female contraception.
  • IM and IM injections should be administered not by the patient but by an appropriately trained health care professional.
  • the method of the present invention does not rely on IM adrninistration but rather subcutaneous adrninistration which can be done by the patient.
  • SUMMARY OF INVENTION Disclosed is a method of human female contraception which comprises subcutaneous administration of a contraceptively effective amount of a contraceptive agent selected from the group consisting of a progestogen and a progestogen plus an estrogen.
  • DETAILED DESCRIPTION OF THE INVENTION The present invention is a method of human female contraception which comprises subcutaneous adnvinistration of a contraceptively effective amount of a contraceptive agent selected from the group consisting of a progestogen and a progestogen plus an estrogen.
  • the method of the present invention can be practiced by the female patient self administering the subcutaneous injection herself.
  • the patient should be taught by a trained health care professional how to administer the subcutaneous injection of progestogen or progestogen plus estrogen.
  • the patient then injects subcutaneously a contraceptively effective amount as she was directed either approximately once a month or approximately every three months or approximately every six months.
  • the word "approximately” is used because some months have 30 days while others have 31 days.
  • the method of the present invention can be practiced by the administration of a combination of a progestogen plus an estrogen once a month.
  • this method is utilized the female will have a menstrual period every month. At the end of each month time period, normal fertility returns unless the patient uses another injection or some other form of fertility control.
  • US Patent 4,038,389 discloses a 200-600 mg/ml parenteral formulation of medroxyprogesterone acetate.
  • the parenteral formulation can be administered once every month or every 13 weeks (3 months) or every 26 weeks (6 months). Following the contraceptive period, the female has a menstrual period unless she has another IM injection prior to her period.
  • the female may have a series of IM injections of medroxyprogesterone acetate to provide contraception on a continuous basis.
  • the /. Reprod. Fertil., 15, 209-14 (1968) discloses a formulation of medroxyprogesterone acetate (25 mg) and estradiol cypionate (5 mg) which was used in a clinical study by monthly IM injection for female contraception. See also
  • the progestogen be selected from the group consisting of medroxyprogesterone acetate, progesterone, norethindrone, desogestrel and levo- norgestrelit is more preferred that the progestogen be medroxyprogesterone acetate.
  • the estrogen be selected from the group consisting of ethinyl estradiol, estradiol cypionate and estradiol valerate; it is more preferred that the estrogen be estradiol cypionate.
  • the contraceptive agent be medroxyprogesterone acetate or medroxyprogesterone acetate plus estradiol cypionate.
  • the contraceptive method of the present invention is practiced by using a progestogen alone, it is preferred that the progestogen be in a depot form as is well known to those skilled in the art. It is preferred that the contraceptively effective amount for one month be for medroxyprogesterone acetate from about 10 mg to about 50 mg/female, for progesterone from about 25 mg to about 200 mg/female, for northindrone from about 5 mg to about 50 mg/female, for desogestrel from about 1 mg to about 4 mg/female, for levo-norgrestrel from about 0.5 mg to about 2 mg/female; for three months be for medroxyprogesterone acetate from about 100 mg to about 200 mg/female, for progesterone from about 25 mg to about 200 mg/female, for northindrone from about 5 mg to about 50 mg/female, for desogestrel from about 1 mg to about 4 mg/female, for levo-n
  • the dose for one, three and six monthes be from about 20 mg to about 30 mg/female, from about 125 mg to about 175 mg/female and from about 250 mg to about 300 mg/female.
  • the contraceptive method of the present invention is practice by using a progestogen plus an estrogen once a month, the progestogen and estrogen should be in an aqueous suspension. It is preferred that the contraceptively effective amount be: for medroxyprogesterone acetate from about 10 mg to about 50 mg/female, for progesterone from about 25 mg to about 200 mg/female, for northindrone from about 5 mg to about 50 mg/female, for desogestrel from about 1 mg to about 4 mg/female, for levo-norgrestrel from about 0.5 mg to about 2 mg/female.
  • estradiol cypionate from about 2.5 mg to about 20 mg/female, ethinyl estradiol from about 0.5 mg to about 3 mg/female, estradiol valerate from about 2.5 mg to about 20 mg/female. It is preferred the contraceptively effective amount of medroxyprogesterone acetate is from about 20 mg to about 30 mg/female and the contraceptively effective amount of estradiol cypionate is from about 3 to about 10 mg female.
  • the exact dosage and frequency of administration depends on the age, weight, general physical condition of the particular patient, other medication the individual may be taking as is well known to those skilled in the art and can be more accurately determined by measuring the blood level or concentration of the progestogen or progestogen and estrogen in the patient's blood and/or the patient's response to the particular condition being treated.
  • Medroxyprogesterone acetate refers to 17I-hydroxy-6I-methylpregn-4-ene- 3,20-dione 17-acetate.
  • a 78 kg 37 year old female who desires to have sexual intercourse on a regular basis is shown how to give a subcutaneous injection by her physician's nurse. She injects 1.0 ml of a 150 mg/ml of an aqueous suspension of medroxyprogesterone acetate subcutaneous as instructed on the second day of her menstrual period. She has sexual intercourse three times a week with a fertile male and does not become pregnant.
  • a 67 kg 21 year old female who desires to have sexual intercourse on a regular basis is shown how to give a subcutaneous injection by her gynecologist. She injects 2.0 ml of a 150 mg/ml of an aqueous suspension of medroxyprogesterone acetate subcutaneous as instructed on the third day of her menstrual period. She has sexual intercourse for six months with an average of three and a half times a week with a fertile male and does not become pregnant.
  • EXAMPLE 4 40 Year Old Female - Progestogen Plus Estrogen A 71 kg 40 year old female who desires to have sexual intercourse on a regular basis is shown how to give a subcutaneous injection by her physician's nurse.

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

The present invention is a method of human female contraception which comprises subcutaneous administration of a contraceptively effective amount of a contraceptive agent selected from the group consisting of a progestogen and a progestogen plus an estrogen.

Description

SUBCUTANEOUS MEDROXYPROGESTERONE ACETATE FOR CONTRACEPTION
BACKGROUND OF THE INVENTION 1. Field of the Invention
The present invention is a subcutaneous method for adrninistering medroxyprogesterone acetate for female contraceptive use.
2. Description of the Related Art US Patent 3,377,364 (Example 9) discloses medroxyprogesterone acetate. The 1996 Physicians Desk Reference (PDR), pages 2602-2604, discloses that
DEPO-PROVERA, a sterile aqueous suspension of medroxyprogesterone acetate for IM adrmnistration, produces a contraceptive effect for three months in females. Following the three month contraceptive period, the female has a menstrual period and is again fertile unless she has another IM injection prior to her period. The 7. Reprod. Fertil, 15, 209-14 (1968) discloses a clinical study of medroxyprogesterone acetate (25 mg) and estradiol cypionate (5 mg) by monthly IM injection for female contraception in 104 women over a period of from four to 15 mo with no pregnancies. Following each IM injection there is a contraceptive effect for a one month time period following which the female has a menstrual period. Contraception, 56, 353-359 (1997) also discloses a clinical study of medroxyprogesterone acetate (25 mg) and estradiol cypionate (5 mg) by monthly IM injection for female contraception.
These two methods work well to provide contraception to ovulating females who wish to have sexual intercourse and not get pregnant. The major problem is that in both cases the injection is IM and IM injections should be administered not by the patient but by an appropriately trained health care professional. The method of the present invention does not rely on IM adrninistration but rather subcutaneous adrninistration which can be done by the patient.
SUMMARY OF INVENTION Disclosed is a method of human female contraception which comprises subcutaneous administration of a contraceptively effective amount of a contraceptive agent selected from the group consisting of a progestogen and a progestogen plus an estrogen. DETAILED DESCRIPTION OF THE INVENTION The present invention is a method of human female contraception which comprises subcutaneous adnvinistration of a contraceptively effective amount of a contraceptive agent selected from the group consisting of a progestogen and a progestogen plus an estrogen.
The method of the present invention can be practiced by the female patient self administering the subcutaneous injection herself. To provide contraception, the patient should be taught by a trained health care professional how to administer the subcutaneous injection of progestogen or progestogen plus estrogen. The patient then injects subcutaneously a contraceptively effective amount as she was directed either approximately once a month or approximately every three months or approximately every six months. The word "approximately" is used because some months have 30 days while others have 31 days. In addition, it is not critical if the female is off by a day or two or three or four or ... from the exact time to administer the subcutaneous injection because of any reason.
There are two ways to practice the claimed invention. These are either the administration of a progestogen alone or the combination of a progestogen with an estrogen. When adrninistering the progestogen alone it is administered either once a month, or approximately every three months or approximately every six months. When the patient uses the three or six months methods, she will not have a menstrual period during that time. When progestogen alone method is utilized it is preferred that the female administer the subcutaneous injection either approximately every three or approximately every six months. At the end of the one month, three month or six month time period normal fertility returns unless the patient uses another injection or some other form of fertility control.
Alternatively, the method of the present invention can be practiced by the administration of a combination of a progestogen plus an estrogen once a month. When this method is utilized the female will have a menstrual period every month. At the end of each month time period, normal fertility returns unless the patient uses another injection or some other form of fertility control.
The pharmaceutical formulations necessary to practice the present invention are known. US Patent 4,038,389 discloses a 200-600 mg/ml parenteral formulation of medroxyprogesterone acetate. The 1996 Physicians Desk Reference (PDR), pages 2602-2604, discloses a sterile aqueous suspension of medroxyprogesterone acetate (DEPO-PROVERA) for depot IM administration for female contraception containing 150 mg of medroxyprogesterone acetate/ml. The parenteral formulation can be administered once every month or every 13 weeks (3 months) or every 26 weeks (6 months). Following the contraceptive period, the female has a menstrual period unless she has another IM injection prior to her period. The female may have a series of IM injections of medroxyprogesterone acetate to provide contraception on a continuous basis. The /. Reprod. Fertil., 15, 209-14 (1968) discloses a formulation of medroxyprogesterone acetate (25 mg) and estradiol cypionate (5 mg) which was used in a clinical study by monthly IM injection for female contraception. See also
Contraception, 49, 293-301 (1994) at 296 and Contraception, 56, 353-359 (1997) at 353.
It is preferred that the progestogen be selected from the group consisting of medroxyprogesterone acetate, progesterone, norethindrone, desogestrel and levo- norgestrelit is more preferred that the progestogen be medroxyprogesterone acetate.
It is preferred that the estrogen be selected from the group consisting of ethinyl estradiol, estradiol cypionate and estradiol valerate; it is more preferred that the estrogen be estradiol cypionate.
It is preferred that the contraceptive agent be medroxyprogesterone acetate or medroxyprogesterone acetate plus estradiol cypionate.
When the contraceptive method of the present invention is practiced by using a progestogen alone, it is preferred that the progestogen be in a depot form as is well known to those skilled in the art. It is preferred that the contraceptively effective amount for one month be for medroxyprogesterone acetate from about 10 mg to about 50 mg/female, for progesterone from about 25 mg to about 200 mg/female, for northindrone from about 5 mg to about 50 mg/female, for desogestrel from about 1 mg to about 4 mg/female, for levo-norgrestrel from about 0.5 mg to about 2 mg/female; for three months be for medroxyprogesterone acetate from about 100 mg to about 200 mg/female, for progesterone from about 25 mg to about 200 mg/female, for northindrone from about 5 mg to about 50 mg/female, for desogestrel from about 1 mg to about 4 mg/female, for levo-norgrestrel from about 0.5 mg to about 2 mg/female and for six months be for medroxyprogesterone acetate from about 200 mg to about 500 mg/female, for progesterone from about 25 mg to about 200 mg/female, for northindrone from about 5 mg to about 50 mg/female, for desogestrel from about 1 mg to about 4 mg/female, for levo-norgrestrel from about 0.5 mg to about 2 mg/female. When the progestogen is medroxyprogesterone acetate it is preferred that the dose for one, three and six monthes be from about 20 mg to about 30 mg/female, from about 125 mg to about 175 mg/female and from about 250 mg to about 300 mg/female.
When the contraceptive method of the present invention is practice by using a progestogen plus an estrogen once a month, the progestogen and estrogen should be in an aqueous suspension. It is preferred that the contraceptively effective amount be: for medroxyprogesterone acetate from about 10 mg to about 50 mg/female, for progesterone from about 25 mg to about 200 mg/female, for northindrone from about 5 mg to about 50 mg/female, for desogestrel from about 1 mg to about 4 mg/female, for levo-norgrestrel from about 0.5 mg to about 2 mg/female. and the contraceptively effective amount of estrogen is: for estradiol cypionate from about 2.5 mg to about 20 mg/female, ethinyl estradiol from about 0.5 mg to about 3 mg/female, estradiol valerate from about 2.5 mg to about 20 mg/female. It is preferred the contraceptively effective amount of medroxyprogesterone acetate is from about 20 mg to about 30 mg/female and the contraceptively effective amount of estradiol cypionate is from about 3 to about 10 mg female.
The exact dosage and frequency of administration depends on the age, weight, general physical condition of the particular patient, other medication the individual may be taking as is well known to those skilled in the art and can be more accurately determined by measuring the blood level or concentration of the progestogen or progestogen and estrogen in the patient's blood and/or the patient's response to the particular condition being treated.
DEFINITIONS The definitions and explanations below are for the terms as used throughout this entire document including both the specification and the claims.
Medroxyprogesterone acetate refers to 17I-hydroxy-6I-methylpregn-4-ene- 3,20-dione 17-acetate.
IM refers to intramuscular injection. EXAMPLES
Without further elaboration, it is believed that one skilled in the art can, using the preceding description, practice the present invention to its fullest extent. The following detailed examples describe how to prepare the various compounds and/or perform the various processes of the invention and are to be construed as merely illustrative, and not limitations of the preceding disclosure in any way whatsoever. Those skilled in the art will promptly recognize appropriate variations from the procedures both as to reactants and as to reaction conditions and techniques. EXAMPLE 1 23 Year Old Female - One Month Progestogen A 60 kg 23 year old female who desires to have sexual intercourse on a regular basis is shown how to give a subcutaneous injection by her physician. She injects 0.2 ml of a 150 mg/ml of an aqueous suspension of medroxyprogesterone acetate subcutaneous as instructed on the third day of her menstrual period. She has sexual intercourse twice a week with a fertile male and does not become pregnant. EXAMPLE 2 37 Year Old Female - Three Month Progestogen
A 78 kg 37 year old female who desires to have sexual intercourse on a regular basis is shown how to give a subcutaneous injection by her physician's nurse. She injects 1.0 ml of a 150 mg/ml of an aqueous suspension of medroxyprogesterone acetate subcutaneous as instructed on the second day of her menstrual period. She has sexual intercourse three times a week with a fertile male and does not become pregnant. EXAMPLE 3 21 Year Old Female - Six Month Progestogen
A 67 kg 21 year old female who desires to have sexual intercourse on a regular basis is shown how to give a subcutaneous injection by her gynecologist. She injects 2.0 ml of a 150 mg/ml of an aqueous suspension of medroxyprogesterone acetate subcutaneous as instructed on the third day of her menstrual period. She has sexual intercourse for six months with an average of three and a half times a week with a fertile male and does not become pregnant. EXAMPLE 4 40 Year Old Female - Progestogen Plus Estrogen A 71 kg 40 year old female who desires to have sexual intercourse on a regular basis is shown how to give a subcutaneous injection by her physician's nurse. She injects 1.0 ml of a 150 mg/ml of an aqueous suspension of medroxyprogesterone acetate subcutaneous as instructed on the second day of her menstrual period. She has sexual intercourse three times a week with a fertile male and does not become pregnant.

Claims

1. A method of human female contraception which comprises subcutaneous administration of a contraceptively effective amount of a contraceptive agent selected from the group consisting of a progestogen and a progestogen plus an estrogen.
2. A method of human female contraception according to claim 1 where the progestogen is selected from the group consisting of medroxyprogesterone acetate, progesterone, norethindrone, desogestrel and levo-norgestrel.
3. A method of human female contraception according to claim 1 where the progestogen is medroxyprogesterone acetate.
4. A method of human female contraception according to claim 1 where the estrogen is selected from the group consisting of ethinyl estradiol, estradiol cypionate and estradiol valerate.
5. A method of human female contraception according to claim 1 where the estrogen is estradiol cypionate.
6. A method of human female contraception according to claim 1 where the contraceptive agent is medroxyprogesterone acetate.
7. A method of human female contraception according to claim 1 where the contraceptive agent is medroxyprogesterone acetate plus estradiol cypionate.
8. A method of human female contraception according to claim 1 where when the contraceptively effective amount of progestogen is administered once a month the contraceptively effective amount is: for medroxyprogesterone acetate from about 10 mg to about 50 mg/female, for progesterone from about 25 mg to about 200 mg/female, for northindrone from about 5 mg to about 50 mg/female, for desogestrel from about 1 mg to about 4 mg/female, for levo-norgrestrel from about 0.5 mg to about 2 mg/female.
9. A method of human female contraception according to claim 8 where the contraceptively effective amount of medroxyprogesterone acetate is from about 20 mg to about 30 mg/female.
10. A method of human female contraception according to claim 1 where when the contraceptively effective amount of progestogen is administered every three months the contraceptively effective amount is: for medroxyprogesterone acetate from about 100 mg to about 200 mg/female, for progesterone from about 25 mg to about 200 mg/female, for northindrone from about 5 mg to about 50 mg/female, for desogestrel from about 1 mg to about 4 mg/female, for levo-norgrestrel from about 0.5 mg to about 2 mg/female.
11. A method of human female contraception according to claim 10 where the contraceptively effective amount of medroxyprogesterone acetate is from about 125 mg to about 175 mg/female.
12. A method of human female contraception according to claim 1 where when the contraceptively effective amount of progestogen is administered every six months the contraceptively effective amount is: for medroxyprogesterone acetate from about 200 mg to about 500 mg/female, for progesterone from about 25 mg to about 200 mg/female, for northindrone from about 5 mg to about 50 mg/female, for desogestrel from about 1 mg to about 4 mg/female, for levo-norgrestrel from about 0.5 mg to about 2 mg/female.
13. A method of human female contraception according to claim 12 where the contraceptively effective amount of medroxyprogesterone acetate is from about 250 mg to about 300 mg/female.
14. A method of human female contraception according to claim 1 where both the progestogen and estrogen are administered once every month the contraceptively effective amount of progestogen is for medroxyprogesterone acetate from about 10 mg to about 50 mg/female, for progesterone from about 25 mg to about 200 mg/female, for northindrone from about 5 mg to about 50 mg/female, for desogestrel from about 1 mg to about 4 mg/female, for levo-norgrestrel from about 0.5 mg to about 2 mg/female. and the contraceptively effective amount of estrogen is for estradiol cypionate from about 2.5 mg to about 20 mg/female, ethinyl estradiol from about 0.5 mg to about 3 mg/female, estradiol valerate from about 2.5 mg to about 20 mg/female.
15. A method of human female contraception according to claim 14 where the contraceptively effective amount of medroxyprogesterone acetate is from about 20 mg to about 30 mg/female and the contraceptively effective amount of estradiol cypionate is from about 3 to about 10 mg/female.
16. A method of human female contraception according to claim 6 where the contraceptively effective amount of progestogen is administered either approximately every 3 or approximately every 6 months.
EP99933540A 1998-07-17 1999-07-09 Subcutaneous medroxyprogesterone acetate for contraception Withdrawn EP1098653A2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US9317198P 1998-07-17 1998-07-17
US93171P 1998-07-17
US10369998P 1998-10-09 1998-10-09
US103699P 1998-10-09
US12682499P 1999-03-30 1999-03-30
US126824P 1999-03-30
PCT/US1999/014129 WO2000003678A2 (en) 1998-07-17 1999-07-09 Subcutaneous medroxyprogesterone acetate for contraception

Publications (1)

Publication Number Publication Date
EP1098653A2 true EP1098653A2 (en) 2001-05-16

Family

ID=27377447

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99933540A Withdrawn EP1098653A2 (en) 1998-07-17 1999-07-09 Subcutaneous medroxyprogesterone acetate for contraception

Country Status (4)

Country Link
EP (1) EP1098653A2 (en)
JP (1) JP2002520346A (en)
AU (1) AU4957999A (en)
WO (1) WO2000003678A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834931A1 (en) * 1998-07-28 2000-02-24 Jenapharm Gmbh Use of biogenic estrogens for hormone replacement therapy
ES2602134T3 (en) 2009-04-14 2017-02-17 Laboratoire Hra Pharma Contraceptive procedure on demand
EP2399566A1 (en) * 2010-06-28 2011-12-28 Laboratoire HRA Pharma Once-a-month method of contraception

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU686736A1 (en) * 1977-02-10 1979-09-25 Всесоюзный Научно-Исследовательский Институт Акушерства И Гинекологии Method of treating endocrine gynecologic diseases
SU724127A1 (en) * 1977-02-10 1980-03-30 Всесоюзный Научно-Исследовательский Институт Акушерства И Гинекологии Ovary function determining method
GB8313921D0 (en) * 1983-05-19 1983-06-22 World Health Org Contraceptive compositions
US4826831A (en) * 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
ES2054784T3 (en) * 1987-08-08 1994-08-16 Akzo Nv A METHOD FOR THE MANUFACTURE OF AN IMPLANT.
HU222501B1 (en) * 1991-06-28 2003-07-28 Endorecherche Inc. Controlled release pharmaceutical composition containing mpa or mga and process for its preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0003678A2 *

Also Published As

Publication number Publication date
JP2002520346A (en) 2002-07-09
WO2000003678A2 (en) 2000-01-27
AU4957999A (en) 2000-02-07
WO2000003678A3 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
EP0911029B1 (en) Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
EP1539184B1 (en) Estrogen replacement regimen
Darney Hormonal implants: contraception for a new century
DK351887D0 (en) COMBINATION DOSAGE FOR HORMONE TREATMENT AND CONTRACTION FOR WOMEN IN PRAEMENOPAUSUS
PL172790B1 (en) Set for substitutive hormonal therapy of a female patient or for contraception of such patient
PT646008E (en) MINIMIZATION OF SECONDARY HEMORRHAGES ASSOCIATED WITH PROGESTINA
Coney et al. The effects on ovarian activity of a monophasic oral contraceptive with 100 μg levonorgestrel and 20 μg ethinyl estradiol
EP1052980A1 (en) Subcutaneous medroxyprogesterone acetate for treatment of menopause and endometriosis
US20030018018A1 (en) Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
Foran New contraceptive choices across reproductive life
EP1098653A2 (en) Subcutaneous medroxyprogesterone acetate for contraception
Haiba et al. Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters
Darney Subdermal progestin implant contraception
KR100232833B1 (en) Method of preventing or inhibiting fertilization
MXPA00005593A (en) Subcutaneous medroxyprogesterone acetate for treatment of menopause and endometriosis
BARNES ACTH and cortisone in obstetrics and gynecology
Castracane et al. Changes in oral contraceptive design since the original release. Commentary on The biological history of the Pill by Roy O. Greep
Ruggiero Prescription contraceptives: countering the risks
Smith Depo-Provera (injectable contraceptive)—A review
Severyn Abortifacient drugs and devices: medical and moral dilemmas
Kovacs Luteal contraception
Kaunitz 12. Contraceptive Implants
Akinso Contraceptive Implants
Luukkainen et al. BLEEDING PATTERNS WITH LONG-ACTING STEROIDAL CONTRACEPTIVES
IE84449B1 (en) Contraceptive packages containing oestrogen and progestin

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010122

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20010122;LT PAYMENT 20010122;LV PAYMENT 20010122;MK PAYMENT 20010122;RO PAYMENT 20010122;SI PAYMENT 20010122

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20010718